Agios Pharmaceuticals(NASDAQ) AGIO

Agios creates medicines for rare blood diseases. These treatments help patients manage life-long anemia. The company fixes how cells process energy.

Treating Rare Blood Diseases

• PYRUKYND: Oral medicine for adults with pyruvate kinase (PK) deficiency; treats a rare genetic disorder where red blood cells break down too quickly.
• AQVESME: FDA-approved treatment for anemia in adults with alpha- or beta-thalassemia; helps patients who do or do not require regular blood transfusions.
• Tebapivat: Clinical-stage activator of pyruvate kinase; currently being tested as a potential treatment for lower-risk myelodysplastic syndromes and sickle cell disease.
• AG-181: Investigational stabilizer for phenylalanine hydroxylase; targets phenylketonuria, a genetic condition that causes proteins to build up in the body.

Strategic Moves and Partnerships

• Sold its oncology business to Servier Pharmaceuticals in March 2021 for an initial payment of $1.8 billion.
• Licensed a preclinical treatment candidate from Alnylam Pharmaceuticals in July 2023 to develop therapies for polycythemia vera.
• Sold royalty rights for a brain tumor drug to Royalty Pharma in August 2024 for $905 million.
• Partnered with NewBridge Pharmaceuticals in July 2024 to distribute treatments in the Gulf Council Countries.
• Entered a distribution agreement with Avanzanite Bioscience in June 2025 to expand its reach in Europe and the United Kingdom.

Scientific and Operational Focus

Agios focuses on cellular metabolism to target the root causes of rare genetic blood disorders. The company maintains a global reach through distribution partnerships in the Middle East and Europe.

Recent Financial Performance

• Revenue rose to $20.0 million in Q4 2025, up 86.1% from Q4 2024.
• Gross profit reached $19.3 million in Q4 2025, up 104.3% year-over-year.
• Operating cash flow was negative $96.2 million in Q4 2025, an improvement of 27.8% from Q4 2024.
• Net loss for the full year 2025 was $412.8 million, compared to a net income of $673.7 million in 2024.

The Road Ahead

Agios has transitioned from a research firm to a commercial leader in rare blood disorders. Its strategy relies on using metabolic science to expand into multiple underserved genetic diseases.